Til sammenligning var bivirkningsincidensen 7, 1% hos de patienter, der blev behandlet med placebo og glimepirid/ metformin.
22 with glimepiride and metformin was 18.1% compared to treatment with the addition of placebo to the ongoing treatment with glimepiride and metformin which was 7.1%.